Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome
Divya Bhatia(Hypertension Institute), Arvind Bagga(All India Institute of Medical Sciences), Dipendra Kumar Mitra(All India Institute of Medical Sciences), Pankaj Hari(Indian Council of Medical Research), Shailaja Sopory(Government of India), Aditi Sinha, Himanshi Saini(All India Institute of Medical Sciences), Savita Saini(All India Institute of Medical Sciences), Mamta Puraswani(All India Institute of Medical Sciences)
Cited by 64
Related Papers
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415
Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome
|Journal of the American Society of Nephrology|2010|296
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|256
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
|Kidney International|2013|216
Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome
|Clinical Journal of the American Society of Nephrology|2010|203